By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Janssen Pharmaceutica N.V. 

Turnhoutseweg 30

Beerse  Antwerpen  2340  Belgium
Phone: 32-14602226 Fax:




Vertex Pharmaceuticals (MA)  (telaprevir for HCV) - Europe, South America, Australia, the Middle East and other countries

Company News
Galapagos NV (GLPG.BR) Initiates Phase 1 Study With GLPG1690, Triggering €6.6 M Milestone In The Alliance With Janssen Pharmaceutica N.V. 7/1/2014 9:13:37 AM
Janssen Pharmaceutica N.V. To Present New Simeprevir Data At The International Liver Congress™ 2014 Of The European Association For The Study Of The Liver (EASL) 3/24/2014 9:49:06 AM
Janssen Pharmaceutica N.V. Release: New Data Show XEPLION® Significantly Delays Time To Relapse Compared To Treatment As Usual With Oral Antipsychotic Monotherapy 3/4/2014 9:59:54 AM
Jubilant BioSys Ltd. Announces Expansion Of Drug Discovery Alliance With Janssen Pharmaceutica N.V. 2/19/2014 7:14:37 AM
Janssen Pharmaceutica N.V. Unveils New Data On Xeplion® In Various Stages Of Schizophrenia 12/1/2013 10:02:42 PM
Galapagos NV (GLPG.BR) Initiates Phase 1 Trial as Part of Its Alliance With Janssen Pharmaceutica N.V. 7/2/2013 10:43:47 AM
Janssen Pharmaceutica N.V., Funds New Global Mental Health Scholarships as Part of Its Healthy Minds Program 3/5/2013 1:09:43 PM
Galapagos NV (GLPG.BR) Delivers Candidate Drug in Its Alliance With Janssen Pharmaceutica N.V. and Receives $5.3 Million Milestone Payment 1/16/2013 8:53:53 AM
New Janssen Pharmaceutica N.V. Data Demonstrate STELARA® (ustekinumab) is Effective, Well-Tolerated and Improved Quality of Life in Patients With Moderate to Severe Plaque Psoriasis 9/28/2012 10:07:12 AM
ImmuNext Enters Into a Strategic Partnership With Janssen Pharmaceutica N.V. to Develop Novel Immunotherapies for the Treatment of Cancer 9/5/2012 9:59:40 AM